BiotechTube

Iadademstat + Gilteritinib Oral Tablet

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia, in Relapse

Conditions

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Trial Timeline

Nov 14, 2022 → Nov 30, 2025

NCT ID
NCT05546580

About Iadademstat + Gilteritinib Oral Tablet

Iadademstat + Gilteritinib Oral Tablet is a phase 1 stage product being developed by Oryzon Genomics for Acute Myeloid Leukemia, in Relapse. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05546580. Target conditions include Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05546580Phase 1Recruiting

Competing Products

20 competing products in Acute Myeloid Leukemia, in Relapse

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Oryzon Genomics

Iadademstat + PaclitaxelPhase 2
44
vafidemstat + PlaceboPhase 2
44
ORY-2001 Low dose + ORY-2001 High dose + PlaceboPhase 2
44
Iadademstat + AtezolizumabPhase 1
25
Azacitidine + Iadademstat + VenetoclaxPhase 1
25